{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:44:30Z","timestamp":1770831870703,"version":"3.50.1"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1707","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) has now received FDA approval for use in adults 50-59 years old who are at increased risk for lower respiratory tract disease (LRTD) caused by RSV. It was previously approved only for adults \u226560 years old.<\/jats:p>","DOI":"10.58347\/tml.2024.1707a","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:19:07Z","timestamp":1723735147000},"page":"113-114","source":"Crossref","is-referenced-by-count":7,"title":["In Brief: RSV Vaccine (Arexvy) for Ages 50-59"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2024,7,22]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:19:08Z","timestamp":1723735148000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1707a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":0,"journal-issue":{"issue":"1707","published-online":{"date-parts":[[2024,7,22]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1707a","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]}}}